GLP-1 therapies have become a key part of todays diabetes treatment algorithm, helping providers balance glucose control, cardiovascular risk, and patient preferences
Lau DC, Erichsen L, Francisco AM, Satylganova A, le Roux CW, McGowan B, et al
According to KFF polling, about half (56%) of GLP-1 users say these drugs were difficult to afford, including one in four who say they were very difficult to afford
Layer P, Holst JJ, Grandt D, and Goebell H
Sounds like big risks for very little potential reward Join the conversation
Unlike some medications that require careful tapering, GLP-1 drugs such as semaglutide, dulaglutide, and liraglutide do not typically cause physical dependence or withdrawal symptoms